ZA939573B - Compositions of L-DOPA esters. - Google Patents

Compositions of L-DOPA esters.

Info

Publication number
ZA939573B
ZA939573B ZA939573A ZA939573A ZA939573B ZA 939573 B ZA939573 B ZA 939573B ZA 939573 A ZA939573 A ZA 939573A ZA 939573 A ZA939573 A ZA 939573A ZA 939573 B ZA939573 B ZA 939573B
Authority
ZA
South Africa
Prior art keywords
active ingredient
dopa
compositions
composition
amount
Prior art date
Application number
ZA939573A
Other languages
English (en)
Inventor
Isaac Milman
Alexander Veinberg
Daphne Atlas
Eldad Melamed
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Publication of ZA939573B publication Critical patent/ZA939573B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA939573A 1992-12-24 1993-12-21 Compositions of L-DOPA esters. ZA939573B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA

Publications (1)

Publication Number Publication Date
ZA939573B true ZA939573B (en) 1994-08-11

Family

ID=25542272

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA939573A ZA939573B (en) 1992-12-24 1993-12-21 Compositions of L-DOPA esters.

Country Status (21)

Country Link
US (2) US5354885A (de)
EP (2) EP0610595B1 (de)
JP (1) JPH07285860A (de)
CN (1) CN1083262C (de)
AT (2) ATE196081T1 (de)
AU (1) AU684053B2 (de)
CA (1) CA2112160A1 (de)
CY (1) CY2214B1 (de)
DE (2) DE69329400T2 (de)
DK (2) DK0867179T3 (de)
ES (2) ES2150294T3 (de)
FI (1) FI107994B (de)
GR (2) GR3030073T3 (de)
HK (1) HK1012577A1 (de)
HU (1) HU218906B (de)
IL (1) IL108147A (de)
LV (1) LV12766B (de)
NO (1) NO305932B1 (de)
NZ (1) NZ250541A (de)
PT (1) PT867179E (de)
ZA (1) ZA939573B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
WO1997016181A1 (en) * 1995-11-03 1997-05-09 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
ATE219358T1 (de) * 1995-11-06 2002-07-15 Somerset Pharmaceuticals Inc Sublinguale und bukkale verabreichung von selegilin
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
BR9908713A (pt) 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
IL143071A0 (en) * 1998-11-10 2002-04-21 Teva Pharma Dispersible compositions containing l-dopa ethyl ester
IL143070A (en) * 1998-11-10 2004-03-28 Teva Pharma Process for the manufacture of l-dopa ethyl ester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
AU2002340470A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
WO2003042136A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
ES2609482T3 (es) 2002-03-20 2017-04-20 Civitas Therapeutics, Inc. Administración pulmonar de levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
WO2004096141A2 (en) * 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
EP1670450B8 (de) * 2003-08-29 2011-03-23 Centocor Ortho Biotech Inc. Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
MXPA06003725A (es) * 2003-10-08 2006-06-23 Mallinckrodt Inc Solucion de fenidato de metilo y metodos asociados de administracion y produccion.
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
HUE028777T2 (en) * 2006-02-17 2017-01-30 Ratiopharm Gmbh Deuterated catecholamine derivatives and medicaments containing these compounds
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
AU2016313138A1 (en) * 2015-08-27 2018-03-15 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
EP3518920A1 (de) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa-derivate zur behandlung von neurologischen erkrankungen
ES2965284T3 (es) 2021-02-09 2024-04-11 Biobab R&D S L Método y uso de un enantiómero de 3,4-dihidroxifenilalanina (DOPA) para potenciar el atractivo de las plantas para los insectos beneficiosos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Also Published As

Publication number Publication date
DK0867179T3 (da) 2000-11-06
PT867179E (pt) 2000-12-29
CA2112160A1 (en) 1994-06-25
HU9303748D0 (en) 1994-04-28
ES2132170T3 (es) 1999-08-16
DE69324466T2 (de) 1999-11-25
AU684053B2 (en) 1997-12-04
ATE178793T1 (de) 1999-04-15
IL108147A0 (en) 1994-04-12
IL108147A (en) 1998-09-24
HUT68498A (en) 1995-06-28
NO934768L (no) 1994-06-27
LV12766A (lv) 2001-12-20
EP0610595B1 (de) 1999-04-14
CN1083262C (zh) 2002-04-24
NO934768D0 (no) 1993-12-22
DE69329400T2 (de) 2001-01-18
FI935847A (fi) 1994-06-25
NO305932B1 (no) 1999-08-23
LV12766B (en) 2002-03-20
FI107994B (fi) 2001-11-15
EP0867179B1 (de) 2000-09-06
HK1012577A1 (en) 1999-08-06
EP0610595A3 (en) 1994-09-21
CN1094950A (zh) 1994-11-16
GR3034867T3 (en) 2001-02-28
DE69324466D1 (de) 1999-05-20
HU218906B (hu) 2000-12-28
ES2150294T3 (es) 2000-11-16
JPH07285860A (ja) 1995-10-31
AU5257793A (en) 1994-07-07
DK0610595T3 (da) 1999-10-25
CY2214B1 (en) 2002-11-08
US5525631A (en) 1996-06-11
DE69329400D1 (de) 2000-10-12
EP0867179A1 (de) 1998-09-30
GR3030073T3 (en) 1999-07-30
FI935847A0 (fi) 1993-12-23
ATE196081T1 (de) 2000-09-15
NZ250541A (en) 1995-12-21
EP0610595A2 (de) 1994-08-17
US5354885A (en) 1994-10-11

Similar Documents

Publication Publication Date Title
AU684053B2 (en) Compositions of L-DOPA esters
IL133585A0 (en) Soluble prodrugs of paclitaxel
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
IL106253A0 (en) Controlled release oral solid pharmaceutical dosage form and its preparation
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
MY125662A (en) Pharmaceutical formulations containing darifenacin
CA2352544A1 (en) Use of long-chain n-alkyl derivatives of deoxynojirimycin for the manufacture of a medicament for the treatment of glycolipid storage diseases
CA2202397A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
JPS6468320A (en) Remedy for psychotic disease or like and therapeutical solution
HU900591D0 (en) Regulated agent-dissolving safety system and process of it's preparation
BG100246A (en) N-substituted azaheterocylic carboxylic acids and their esters
UA66751C2 (en) Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
CA2237643A1 (en) Therapeutic agent for acute hepatic failure
MX9801192A (es) Nuevos peptidos opioides.
RU97105771A (ru) Способ лечения сахарного диабета
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств
MX9707394A (es) Formulaciones de ridogrel de dosis baja y su uso para el tratamiento de enfermedades intestinales inflamatorias.